Biomind Labs Inc. (NEO: BMND)

Canada flag Canada · Delayed Price · Currency is CAD
0.300
0.00 (0.00%)
Jan 17, 2025, 4:00 PM EST
140.00%
Market Cap 78.26M
Revenue (ttm) n/a
Net Income (ttm) -952.15K
Shares Out n/a
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 267
Open 0.300
Previous Close 0.300
Day's Range 0.300 - 0.300
52-Week Range 0.025 - 1.090
Beta 0.08
RSI 37.63
Earnings Date Mar 31, 2025

About Biomind Labs

Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; BMND08, a 5-Metoxi-N,N-dimethyltryptamine based formulation that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer’s-type cognitive impairment; BMND06 is in Phase I clinical trial for treatment of... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Alejandro Antalich
Country Canada
Stock Exchange Cboe Canada
Ticker Symbol BMND
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.